Press coverage about Halozyme Therapeutics (NASDAQ:HALO) has trended positive this week, according to Accern. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Halozyme Therapeutics earned a news impact score of 0.31 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.6622598020125 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Halozyme Therapeutics, Inc. (NASDAQ:HALO) Upgraded at Zacks Investment Research (americanbankingnews.com)
- See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc. (finance.yahoo.com)
- Jefferies Group Comments on Halozyme Therapeutics, Inc.’s Q3 2017 Earnings (HALO) (americanbankingnews.com)
- Positive Press Coverage Very Likely to Affect RSP Permian (RSPP) Share Price (vothemes.com)
- Halozyme Therapeutics, Inc. (HALO) Rating Reiterated by Jefferies Group LLC (americanbankingnews.com)
Shares of Halozyme Therapeutics (NASDAQ HALO) traded down 1.90% during mid-day trading on Friday, reaching $11.90. 865,040 shares of the company traded hands. Halozyme Therapeutics has a 52-week low of $8.18 and a 52-week high of $15.20. The company’s market capitalization is $1.59 billion. The firm’s 50 day moving average price is $13.12 and its 200-day moving average price is $13.12.
Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.02. The company had revenue of $33.80 million during the quarter, compared to analysts’ expectations of $31.76 million. The firm’s revenue was up 1.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.21) EPS. Equities analysts predict that Halozyme Therapeutics will post ($0.97) earnings per share for the current fiscal year.
HALO has been the subject of several recent research reports. BidaskClub raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 24th. Zacks Investment Research lowered shares of Halozyme Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, May 3rd. Barclays PLC reissued an “overweight” rating and issued a $16.00 price objective on shares of Halozyme Therapeutics in a research note on Friday, June 23rd. BMO Capital Markets initiated coverage on shares of Halozyme Therapeutics in a research note on Monday, April 17th. They issued a “market perform” rating and a $14.00 price objective for the company. Finally, ValuEngine raised shares of Halozyme Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $14.75.
ILLEGAL ACTIVITY NOTICE: “Halozyme Therapeutics (HALO) Receiving Positive Press Coverage, Accern Reports” was published by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/2809290/halozyme-therapeutics-halo-receiving-positive-press-coverage-accern-reports.html.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.